Background: Silver nanoparticles (AgNPs) can be used as vehicles
to transport drug molecules to target zones and there by improve
their therapeutical efficacy. Aim: The aim of the present work was
to assess the effect of nitazoxanide loaded on silver nanoparticles
(AgNps) in treatment of chronic toxoplasmosis in mice. Materials
and methods: Mice were infected with T. gondii Me49 non-virulent
strain and divided into 2 subgroups according to the time of starting
treatment, and each subgroup sub divided into 7 groups. GI: Non
infected- non- treated, GII: Infected non-treated mice, GIII: Infected
and treated by spiramycin, GIV: Infected and treated by
nitazoxanide, GVa: Infected and treated by nitazoxanide loaded on
silver nanoparticles, GVb: Infected and treated by nanosilver only,
GVI: infected and treated by combination of nitazoxanide and
spiramycin, GVII: infected and treated by combination of
nitazoxanide loaded on silver nanoparticles and spiramycin. Effect
of treatment was assessed by counting the number of T. gondii brain
cysts, histopathology and scanning electron microscopy. Results:
Nitazoxanide loaded on AgNps significantly reduced the number of
T. gondii brain tissue cysts and improved the inflammatory and
pathological changes in brain tissue sections in treated groups as
compared to the other groups. It also affects the normal architecture
and size of tissue cysts in brain. Conclusion: Nitazoxanide loaded
on AgNps proved their effectiveness against the experimental chronic Toxoplasma infection. |
